DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $885 | -30.0% | 42,901 | +0.1% | 0.05% | -25.0% |
| Q2 2023 | $1,265 | +11.4% | 42,863 | -13.0% | 0.06% | +25.5% |
| Q1 2023 | $1,136 | -17.0% | 49,267 | +0.1% | 0.05% | -22.7% |
| Q4 2022 | $1,368 | -99.9% | 49,228 | -0.3% | 0.07% | -9.6% |
| Q3 2022 | $1,514,000 | -5.8% | 49,380 | -9.6% | 0.07% | +4.3% |
| Q2 2022 | $1,607,000 | -23.9% | 54,638 | -16.8% | 0.07% | -15.7% |
| Q1 2022 | $2,111,000 | -27.9% | 65,638 | 0.0% | 0.08% | -7.8% |
| Q4 2021 | $2,927,000 | -18.8% | 65,638 | -8.2% | 0.09% | -23.1% |
| Q3 2021 | $3,606,000 | -38.9% | 71,466 | -5.0% | 0.12% | -40.3% |
| Q2 2021 | $5,902,000 | +501.0% | 75,245 | +337.3% | 0.20% | +460.0% |
| Q1 2021 | $982,000 | -30.0% | 17,206 | +2.8% | 0.04% | -27.1% |
| Q4 2020 | $1,402,000 | -0.8% | 16,733 | -57.6% | 0.05% | +4.3% |
| Q3 2020 | $1,414,000 | +86.8% | 39,497 | +26.0% | 0.05% | +119.0% |
| Q2 2020 | $757,000 | – | 31,339 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $219,569,000 | 28.65% |
| ARCH Venture Management, LLC | 5,168,749 | $152,116,000 | 18.54% |
| Casdin Capital, LLC | 1,500,000 | $44,145,000 | 3.73% |
| Flagship Pioneering Inc. | 2,619,968 | $77,106,000 | 2.90% |
| Yiheng Capital Management, L.P. | 1,014,684 | $29,862,000 | 1.71% |
| SECTORAL ASSET MANAGEMENT INC | 202,100 | $5,948,000 | 1.20% |
| GILDER GAGNON HOWE & CO LLC | 1,956,820 | $57,589,000 | 1.03% |
| Artal Group S.A. | 600,000 | $17,658,000 | 0.94% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $158,024,002 | 0.87% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $283,000 | 0.69% |